Leiomyosarcoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Nima Nasiri (talk | contribs) No edit summary |
Nima Nasiri (talk | contribs) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
== Overview: == | == Overview: == | ||
[[Leiomyosarcoma]] is one the most common types of soft tissue sarcoma. | [[Leiomyosarcoma]] is one the most common types of soft tissue [[sarcoma]]. [[Sarcoma]]<nowiki/>s of the [[uterine]] [[cervix]] constitute less than 1% of all cervical malignancies. Although leiomyosarcoma is one of the most common non-[[epithelial]] malignant neoplasms arising in [[soft tissue]] and [[somatic]] organs, while arising from the [[uterine]] [[cervix]] is extremely rare. Annual incidence of leiomyosarcomas is approximately 0.4 to 0.64 per 100,000 women in the United States, which is increasing in [[postmenopausal]] women, usually after age 50. | ||
__NOTOC__ | __NOTOC__ | ||
| Line 6: | Line 6: | ||
==Epidemiology and demographics== | ==Epidemiology and demographics== | ||
* [[Leiomyosarcoma]] is an aggressive soft tissue sarcoma which accounts for 1% of all uterine malignancies, but contributes to a significant proportion of [[uterine]] cancer deaths. | * [[Leiomyosarcoma]] is an aggressive soft tissue [[sarcoma]] which accounts for 1% of all uterine malignancies, but contributes to a significant proportion of [[uterine]] cancer deaths. | ||
* The incidence of uterine LMS is 0.36 per 100,000 woman-years in the United States; mostly occur in women over 40 years of age, with incidence increasing rapidly after age 50.<ref>{{cite journal|doi=10.1111/j.1525-1438.2007.01025.x | * The incidence of uterine LMS is 0.36 per 100,000 woman-years in the United States; mostly occur in women over 40 years of age, with incidence increasing rapidly after age 50.<ref name="pmid18334013">{{cite journal |vauthors=Lavie O, Barnett-Griness O, Narod SA, Rennert G |title=The risk of developing uterine sarcoma after tamoxifen use |journal=Int. J. Gynecol. Cancer |volume=18 |issue=2 |pages=352–6 |date=2008 |pmid=18334013 |doi=10.1111/j.1525-1438.2007.01025.x |url=}}</ref> | ||
* Black women have a 2-fold higher [[incidence]] than white women. | * Black women have a 2-fold higher [[incidence]] than white women. | ||
* LMS may be associated with [[obesity]] and [[diabetes]]. | * LMS may be associated with [[obesity]] and [[diabetes]]. | ||
* [[Tamoxifen]] use for N5 years may also increase LMS risk to 17 per 100,000 woman-years.<ref name="ToroTravis20062">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref> | * [[Tamoxifen]] use for N5 years may also increase LMS risk to 17 per 100,000 woman-years.<ref name="ToroTravis20062">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref> | ||
* Additionally, studies in soft tissue sarcoma have attributed an increased risk of LMS with [[p53]] gene mutations, [[radiation]] treatment for childhood cancers, and [[germ line]] [[mutations]] in [[fumarate hydratase]] (hereditary [[leiomyomatosis]] with [[renal cell carcinoma]]) <ref name="AbelerRøyne2009">{{cite journal|last1=Abeler|first1=Vera M|last2=Røyne|first2=Odd|last3=Thoresen|first3=Steinar|last4=Danielsen|first4=Håvard E|last5=Nesland|first5=Jahn M|last6=Kristensen|first6=Gunnar B|title=Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients|journal=Histopathology|volume=54|issue=3|year=2009|pages=355–364|issn=03090167|doi=10.1111/j.1365-2559.2009.03231.x}}</ref> | * Additionally, studies in soft tissue sarcoma have attributed an increased risk of LMS with [[p53]] gene mutations, [[radiation]] treatment for childhood cancers, and [[germ line]] [[mutations]] in [[fumarate hydratase]] (hereditary [[leiomyomatosis]] with [[renal cell carcinoma]]) <ref name="AbelerRøyne2009">{{cite journal|last1=Abeler|first1=Vera M|last2=Røyne|first2=Odd|last3=Thoresen|first3=Steinar|last4=Danielsen|first4=Håvard E|last5=Nesland|first5=Jahn M|last6=Kristensen|first6=Gunnar B|title=Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients|journal=Histopathology|volume=54|issue=3|year=2009|pages=355–364|issn=03090167|doi=10.1111/j.1365-2559.2009.03231.x}}</ref> | ||
* Most uterine LMS is unassociated with preexisting leiomyomas and no biologic evidence exists to link LMS with their benign, [[smooth muscle]] [[uterine]] tumors. <ref name="ToroTravis2006">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref> | * Most uterine LMS is unassociated with preexisting leiomyomas and no biologic evidence exists to link LMS with their benign, [[smooth muscle]] [[uterine]] tumors. <ref name="ToroTravis2006">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref> | ||
==References== | ==References== | ||
Latest revision as of 15:06, 4 April 2019
Overview:
Leiomyosarcoma is one the most common types of soft tissue sarcoma. Sarcomas of the uterine cervix constitute less than 1% of all cervical malignancies. Although leiomyosarcoma is one of the most common non-epithelial malignant neoplasms arising in soft tissue and somatic organs, while arising from the uterine cervix is extremely rare. Annual incidence of leiomyosarcomas is approximately 0.4 to 0.64 per 100,000 women in the United States, which is increasing in postmenopausal women, usually after age 50.
|
Leiomyosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Leiomyosarcoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Leiomyosarcoma epidemiology and demographics |
|
Risk calculators and risk factors for Leiomyosarcoma epidemiology and demographics |
Epidemiology and demographics
- Leiomyosarcoma is an aggressive soft tissue sarcoma which accounts for 1% of all uterine malignancies, but contributes to a significant proportion of uterine cancer deaths.
- The incidence of uterine LMS is 0.36 per 100,000 woman-years in the United States; mostly occur in women over 40 years of age, with incidence increasing rapidly after age 50.[1]
- Black women have a 2-fold higher incidence than white women.
- LMS may be associated with obesity and diabetes.
- Tamoxifen use for N5 years may also increase LMS risk to 17 per 100,000 woman-years.[2]
- Additionally, studies in soft tissue sarcoma have attributed an increased risk of LMS with p53 gene mutations, radiation treatment for childhood cancers, and germ line mutations in fumarate hydratase (hereditary leiomyomatosis with renal cell carcinoma) [3]
- Most uterine LMS is unassociated with preexisting leiomyomas and no biologic evidence exists to link LMS with their benign, smooth muscle uterine tumors. [4]
References
- ↑ Lavie O, Barnett-Griness O, Narod SA, Rennert G (2008). "The risk of developing uterine sarcoma after tamoxifen use". Int. J. Gynecol. Cancer. 18 (2): 352–6. doi:10.1111/j.1525-1438.2007.01025.x. PMID 18334013.
- ↑ Toro, Jorge R.; Travis, Lois B.; Wu, Hongyu Julian; Zhu, Kangmin; Fletcher, Christopher D.M.; Devesa, Susan S. (2006). "Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases". International Journal of Cancer. 119 (12): 2922–2930. doi:10.1002/ijc.22239. ISSN 0020-7136.
- ↑ Abeler, Vera M; Røyne, Odd; Thoresen, Steinar; Danielsen, Håvard E; Nesland, Jahn M; Kristensen, Gunnar B (2009). "Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients". Histopathology. 54 (3): 355–364. doi:10.1111/j.1365-2559.2009.03231.x. ISSN 0309-0167.
- ↑ Toro, Jorge R.; Travis, Lois B.; Wu, Hongyu Julian; Zhu, Kangmin; Fletcher, Christopher D.M.; Devesa, Susan S. (2006). "Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases". International Journal of Cancer. 119 (12): 2922–2930. doi:10.1002/ijc.22239. ISSN 0020-7136.